INTRAVITREAL RANIBIZUMAB TREATMENT FOR ADVANCED FAMILIAL EXUDATIVE VITREORETINOPATHY WITH HIGH VASCULAR ACTIVITY.
INTRAVITREAL RANIBIZUMAB TREATMENT FOR ADVANCED FAMILIAL EXUDATIVE VITREORETINOPATHY WITH HIGH VASCULAR ACTIVITY.
复制标题
玻璃体腔内雷比珠单抗治疗高血管活性的晚期家族性渗出性玻璃体视网膜病变
DOI：
10.1097/iae.0000000000003122
复制
发表时间：
2021-09-01
期刊：
影响因子：
--
通讯作者：
Zhao P
中科院分区：
文献类型：
--
作者：
Lyu J;Zhang Q;Xu Y;Zhang X;Fei P;Zhao P
补充数字内容在文本中可用。回顾性干预性病例研究证实了玻璃体内注射雷珠单抗对不同临床和遗传背景的晚期家族性渗出性玻璃体视网膜病变伴高血管活动的有效性。目的：确定玻璃体内雷珠单抗（IVR）治疗具有高血管活性的晚期家族性渗出性玻璃体视网膜病变的疗效。研究方法：回顾性干预性病例系列包括28只眼（20例患者），这些患者接受IVR联合或不联合其他治疗，治疗3 - 5期家族性渗出性玻璃体视网膜病变伴活动性纤维血管增生和显著视网膜下渗出。治疗后的眼底特征，相关的临床变量和基因突变的结果措施。结果：首次IVR时患者的年龄范围为0.2至36个月。每只眼睛平均接受1.3次IVR注射。IVR后家族性渗出性玻璃体视网膜病变消退16眼（57%），进展12眼（43%）。13眼行激光和/或玻璃体切割术。随访24 ~ 58个月，22眼（78%）视网膜复位。与IVR后进展相关的临床变量是预先存在的纤维血管增生超过一个象限和初始注射后持续的血管活动（P < 0.05）。11例患者的家族性渗出性玻璃体视网膜病变致病基因突变与IVR治疗的可变反应相关。结论：玻璃体内雷珠单抗治疗可以有效地使具有高血管活性的晚期家族性渗出性玻璃体视网膜病变消退。不同的治疗结果可能与家族性渗出性玻璃体视网膜病变的不同表现和遗传异质性有关。
Supplemental Digital Content is Available in the Text. The retrospective interventional case study demonstrated the efficacy of intravitreal injection of ranibizumab for advanced familial exudative vitreoretinopathy with high vascular activity, in patients with varying clinical and genetic backgrounds. Purpose: To determine the efficacy of intravitreal ranibizumab (IVR) treatment for advanced familial exudative vitreoretinopathy with high vascular activity. Methods: The retrospective interventional case series included 28 eyes (20 patients) that had IVR in combination or not with other treatment, for Stage 3 to 5 familial exudative vitreoretinopathy with active fibrovascular proliferation and prominent subretinal exudation. Outcome measures were fundus features after treatment, associated clinical variables, and genetic mutations. Results: The age of patients at the first IVR ranged from 0.2 to 36 months. An average of 1.3 IVR injections per eye were given. Familial exudative vitreoretinopathy regressed in 16 (57%) eyes and progressed in 12 eyes (43%) after IVR. Laser and/or vitrectomy was performed on 13 eyes. The retina was reattached in 22 eyes (78%) after 24 to 58 months follow-up. Clinical variables associated with progression after IVR were preexisting fibrovascular proliferation over one quadrant and persistent vascular activity after the initial injection (P < 0.05). Familial exudative vitreoretinopathy-causative genetic mutations in 11 patients were related to variable response to IVR treatment. Conclusion: Intravitreal ranibizumab treatment may effectively regress advanced familial exudative vitreoretinopathy with high vascular activity in selected cases. Different treatment outcomes may be relevant to variable presentation and genetic heterogeneity of familial exudative vitreoretinopathy.